Download
00345_2024_Article_4852.pdf 1,80MB
WeightNameValue
1000 Titel
  • Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network
1000 Autor/in
  1. Merseburger, Axel |
  2. Bakshi, Ganesh |
  3. Chen, Dong-Yi |
  4. Chiong, Edmund |
  5. Jabbour, Michel |
  6. Joung, Jae Young |
  7. Lai, Allen Yu-Hung |
  8. Lawrentschuk, Nathan |
  9. Le, Tuan-Anh |
  10. Ng, Chi Fai |
  11. Ng, Choon Ta |
  12. Ong, Teng Aik |
  13. Pang, Jacob See-Tong |
  14. Rabah, Danny M. |
  15. Ragavan, Narasimhan |
  16. Sase, Kazuhiro |
  17. Suzuki, Hiroyoshi |
  18. Teo, Michelle Mui Hian |
  19. Uemura, Hiroji |
  20. Woo, Henry H. |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-03-14
1000 Erschienen in
1000 Quellenangabe
  • 42(1):156
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00345-024-04852-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10940372/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>Androgen deprivation therapy (ADT) is the mainstay approach for prostate cancer (PCa) management. However, the most commonly used ADT modality, gonadotropin-releasing hormone (GnRH) agonists, has been associated with an increased risk of cardiovascular disease (CVD).</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>The PCa Cardiovascular (PCCV) Expert Network, consisting of multinational urologists, cardiologists and oncologists with expertise in managing PCa, convened to discuss challenges to routine cardiovascular risk assessment in PCa management, as well as how to mitigate such risks in the current treatment landscape.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The experts identified several barriers, including lack of awareness, time constraints, challenges in implementing risk assessment tools and difficulties in establishing multidisciplinary teams that include cardiologists. The experts subsequently provided practical recommendations to improve cardio-oncology care for patients with PCa receiving ADT, such as simplifying cardiovascular risk assessment, individualising treatment based on CVD risk categories, establishing multidisciplinary teams and referral networks and fostering active patient engagement. A streamlined cardiovascular risk-stratification tool and a referral/management guide were developed for seamless integration into urologists’ practices and presented herein. The PCCV Expert Network agreed that currently available evidence indicates that GnRH antagonists are associated with a lower risk of CVD than that of GnRH agonists and that GnRH antagonists are preferred for patients with PCa and a high CVD risk.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>In summary, this article provides insights and guidance to improve management for patients with PCa undergoing ADT.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Cardiovascular toxicity
lokal Androgen deprivation therapy
lokal Gonadotropin-Releasing Hormone [MeSH]
lokal Invited Review
lokal Prostatic Neoplasms/chemically induced [MeSH]
lokal Risk Assessment [MeSH]
lokal Cardiovascular disease
lokal Humans [MeSH]
lokal Interdisciplinary
lokal Cardiovascular Diseases/epidemiology [MeSH]
lokal Androgen Antagonists/adverse effects [MeSH]
lokal Prostatic Neoplasms/drug therapy [MeSH]
lokal Risk management
lokal Male [MeSH]
lokal Cardiovascular Diseases/chemically induced [MeSH]
lokal Prostate cancer
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-6467-3931|https://frl.publisso.de/adhoc/uri/QmFrc2hpLCBHYW5lc2g=|https://frl.publisso.de/adhoc/uri/Q2hlbiwgRG9uZy1ZaQ==|https://frl.publisso.de/adhoc/uri/Q2hpb25nLCBFZG11bmQ=|https://frl.publisso.de/adhoc/uri/SmFiYm91ciwgTWljaGVs|https://frl.publisso.de/adhoc/uri/Sm91bmcsIEphZSBZb3VuZw==|https://frl.publisso.de/adhoc/uri/TGFpLCBBbGxlbiBZdS1IdW5n|https://frl.publisso.de/adhoc/uri/TGF3cmVudHNjaHVrLCBOYXRoYW4=|https://frl.publisso.de/adhoc/uri/TGUsIFR1YW4tQW5o|https://frl.publisso.de/adhoc/uri/TmcsIENoaSBGYWk=|https://frl.publisso.de/adhoc/uri/TmcsIENob29uIFRh|https://frl.publisso.de/adhoc/uri/T25nLCBUZW5nIEFpaw==|https://frl.publisso.de/adhoc/uri/UGFuZywgSmFjb2IgU2VlLVRvbmc=|https://frl.publisso.de/adhoc/uri/UmFiYWgsIERhbm55IE0u|https://frl.publisso.de/adhoc/uri/UmFnYXZhbiwgTmFyYXNpbWhhbg==|https://frl.publisso.de/adhoc/uri/U2FzZSwgS2F6dWhpcm8=|https://frl.publisso.de/adhoc/uri/U3V6dWtpLCBIaXJveW9zaGk=|https://frl.publisso.de/adhoc/uri/VGVvLCBNaWNoZWxsZSBNdWkgSGlhbg==|https://frl.publisso.de/adhoc/uri/VWVtdXJhLCBIaXJvamk=|https://frl.publisso.de/adhoc/uri/V29vLCBIZW5yeSBILg==
1000 Hinweis
  • DeepGreen-ID: e1dc93f46a974245bd4464d45b6aa220 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Ferring Pharmaceuticals |
  2. Universität zu Lübeck |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Ferring Pharmaceuticals |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Universität zu Lübeck |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6522018.rdf
1000 Erstellt am 2025-07-06T11:56:13.661+0200
1000 Erstellt von 322
1000 beschreibt frl:6522018
1000 Zuletzt bearbeitet 2025-07-31T15:00:08.912+0200
1000 Objekt bearb. Thu Jul 31 15:00:08 CEST 2025
1000 Vgl. frl:6522018
1000 Oai Id
  1. oai:frl.publisso.de:frl:6522018 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source